ITGAV targeting as a therapeutic approach for treatment of metastatic breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Integrins, like alpha-V beta-3 (α_Vβ₃), are crucial in cancer progression, regulating extracellular matrix remodeling.
• While α_Vβ₃ inhibition is studied, the specific role of the integrin subunit alpha-V gene (ITGAV) in metastatic breast cancer remains unclear.

Purpose of the Study:

• To elucidate the molecular mechanisms by which ITGAV promotes tumorigenesis, metastasis, proliferation, invasion, and self-renewal in breast cancer.
• To evaluate the therapeutic potential of the ITGAV antagonist, cilengitide, in metastatic breast cancer models.

Main Methods:

• ITGAV was silenced (knockdown) to investigate its functional role and molecular targets.
• Gene expression analysis of BCL2 and PXN was performed after ITGAV silencing.
• The efficacy of cilengitide was assessed in vivo using a metastatic breast cancer animal model.
• Publicly available patient data were analyzed to correlate ITGAV expression with patient survival.

Main Results:

• ITGAV overexpression correlated with poor relapse-free survival in breast cancer patients.
• ITGAV knockdown suppressed breast cancer cell proliferation, invasion, and self-renewal by modulating BCL2 and PXN expression.
• Cilengitide treatment significantly reduced lung metastasis in a preclinical metastatic breast cancer model.

Conclusions:

• Overexpression of ITGAV contributes to breast cancer metastasis, partly through the upregulation of PXN.
• Targeting ITGAV represents a potential therapeutic strategy for metastatic breast cancer and primary tumors with high ITGAV expression.
• ITGAV expression levels may serve as predictive biomarkers for patient response to treatment and overall prognosis.